Mr. Alhazmi is a lecturer at Najran University, Saudi Arabia and a PhD candidate at the School of Pharmacy, Faculty of Medicine and Health, The University of Sydney. He has over nine years of experience as a pharmacist and senior clinical pharmacist and five years of academic experience as a lecturer. His research focuses on respiratory care.

Lia Amalia is a senior academic at the School of Pharmacy, Institut Teknologi Bandung (ITB), Indonesia. She earned her doctoral degree in pharmacy from ITB in 2008 and has been a faculty member since 1998. Her expertise lies in clinical and community pharmacy, and she has been actively involved in teaching, curriculum development, and research supervision at both undergraduate and professional levels. Her research interests include rational drug use, pharmaceutical care, and health systems, with a focus on infectious diseases such as tuberculosis. She has contributed to various academic and public health initiatives in Indonesia, particularly in strengthening clinical pharmacy practices and patient-centered care. As the presenting author at this conference, she aims to share insights from retrospective hospital-based data on tuberculosis treatment outcomes and to promote collaborative efforts that advance pharmacy practice in resource-limited and high-burden settings.

Marcelle Appay is a specialist pharmacist in Anticoagulation Stewardship at Westmead Hospital and is currently undertaking her PhD at Sydney University. In this role she works across disciplinary boundaries to develop and implement clinical systems to ensure best possible use of anticoagulants across the organisation and to conduct research. Marcelle has held various leadership positions during her career including as the Team Leader for the pharmacists on the Specialist Medical wards and as a member on the Advanced Pharmacy Australia (AdPha) Cardiology Leadership Committee. Marcelle has been a member of a number of expert groups including the New South Wales Clinical Excellence Commission Anticoagulant Medicines Working Party and the Thrombosis and Haemostasis Society of Australia and New Zealand (THANZ) Anticoagulation Stewardship Network.

Mahad Adnan – B. Pharm (honours) is a graduate from the University of Sydney School of Pharmacy. He is also a practicing community intern pharmacist. Mahad’s research focuses on the quality use of commercially available valerian products in Australian pharmacies, which was explored in his honours thesis under the supervision of Professor Jane Hanrahan, A/ Professor Joanna Harnett and Dr. Jocelin Chan. His research covered a wide range of skills set including analytical chemistry and scoping review. Mahad hopes to continue contributing in research in quality use of complementary medicines.

I am a Master’s student in Pharmacy and a teaching assistant at the Department of Microbiology and Parasitology, Faculty of Pharmacy, University of Medicine and Pharmacy at Ho Chi Minh City (UMP-HCM). I earned my Bachelor's degree in Pharmacy from UMP-HCM in 2024 and am currently pursuing a Master’s in Pharmacology and Clinical Pharmacy. I have over three years of research experience in microbiology and molecular biology, focusing on antimicrobial resistance and efflux mechanisms in Acinetobacter baumannii. I am the recipient of several academic awards, including the UMP-HCM Pharmacy Scholarship and the Second Prize in the Faculty’s Student Scientific Research Competition (2024). My recent work has been presented at the 4th ASEAN PharmNET Conference and published in MedPharmRes.

Hien Duong has over a decade of expertise in nanotechnology. Her research is highly interdisciplinary, focused on nanoscale materials and devices to improve health outcomes. With a background in polymer synthesis and nanomaterial fabrication, her work spans organic, inorganic, and biocompatible nanomaterials for biomedical applications, particularly in treating infectious diseases and cancer. This unique combination of skills gives her a deep understanding of the interface between polymer science and biomedical applications.

Dr. Kaori Fukushige is a Senior Assistant Professor in the Department of Anatomy at Aichi Medical University School of Medicine. She received her first Ph.D. in Pharmaceutical Sciences from Nagoya City University in 2017, where she belonged to the Drug Delivery and Nano Pharmaceutics Laboratory led by Prof. Tetsuya Ozeki. She earned a second Ph.D. in Medical Science from Aichi Medical University in 2024, under the supervision of Prof. Munekazu Naito in the Department of Anatomy. Her research focuses on drug delivery systems (DDS) using nano- and microparticles, with particular interest in modulating cellular responses and enhancing therapeutic efficacy through the use of ultrafine bubbles (UFBs). By leveraging her background in anatomy, she aims to develop innovative DDS strategies that contribute to the advancement of personalized and regenerative medicine.

Prof. Zhonggao Gao is a Professor and Doctoral Supervisor at the Institute of Materia Medica, Chinese Academy of Medical Sciences, and Deputy Director of the Beijing Key Laboratory of Drug Delivery Technology. He earned his Ph.D. from Seoul National University (1998) and conducted postdoctoral research at Harvard University/Northeastern University with Prof. Vladimir P. Torchilin. Specializing in tumor-targeted nanoformulations and gene/polypeptide delivery systems, he developed pH-sensitive nanocarriers and macrophage-targeted gene delivery platforms, publishing over 120 papers in journals including Materials Today and Biomaterials. He leads national projects (e.g., NSFC, Major New Drug Development Program) and serves on the editorial board of Acta Pharmaceutica Sinica B while reviewing for Journal of Controlled Release.

Dr. Taishi Higashi graduated from Kumamoto University in 2004. Thereafter, he received his M.S. in 2006 and Ph.D. in 2009 at Kumamoto University. When he was a doctoral course student, he worked at Evonik Röhm GmbH & Co. (Darmstadt, Germany) as internship for 6 months. After earning his Ph.D., he worked at Taisho Pharmaceutical Co., Ltd. for 2 years. He worked as a Research Associate in Kumamoto University from 2011. He was a postdoctoral fellow at the Faculty of Engineering, National University of Singapore under the supervision of Prof. Dr. Jun Li during 2013–14. Since 2018, he has been Associate Professor of Kumamoto University in Leading Initiative for Excellent Young Researchers. He has been engaged in researching cyclodextrin-based supramolecular pharmaceutical sciences and has published over 140 papers including review articles. He has received eight awards including the Pharmaceutical Society of Japan Award for Young Scientists (2018), etc.

My name is Jung-Ki Hong, a fifth-semester student in the combined M.S.-Ph.D. program in the Department of Manufacturing Pharmacy at Pusan National University. I am currently conducting research in the Laboratory of Biopharmaceutics and Pharmacokinetics, focusing on improving the oral bioavailability of poorly water-soluble natural compounds. My current project involves developing a β-cyclodextrin-stabilized calcium carbonate microcomposite using a biomineralization technique. This formulation significantly enhanced the solubility, intestinal absorption, and oral bioavailability of luteolin, as demonstrated in in vitro, in situ, and in vivo studies. Attending this conference will allow me to share my findings, gain valuable feedback from international experts, and broaden my understanding of global trends in drug delivery systems and pharmacokinetics. I am excited about the opportunity to grow academically and build meaningful connections with fellow researchers in the field.

Mr. Huy Nguyen-Thanh is a committed researcher with expertise in biotechnology and microbiology. As the presenting author of the current project on analysis of gut microbial composition through flow cytometry, he has made significant contributions to advancing flow cytometric fingerprinting for studying dynamic shifts in gut microflora. With a solid academic foundation and extensive hands-on experience in flow cytometry, Mr. Huy has successfully guided the project through critical phases. His work is fueled by a deep passion for microbiology, with a particular focus on the remarkable diversity of gut bacteria and the impacts of various substances on their populations, striving to expand scientific understanding in this vital field. Recognized for his collaborative approach, Mr. Huy is enthusiastic about connecting with fellow researchers and professionals at the conference, aiming to exchange insights, build partnerships, and explore new directions in pharmaceutical research and innovation.

Ngoc Bao Huu Dang is an undergraduate majored in Pharmacy at the University of Medicine and Pharmacy at Ho Chi Minh City. She found interest in the field of microbiology as a freshman. Strongly concerning of the critical raise in antibiotic resistance rate, Ngoc worked hard in studying various mechanisms of either bacterial or fungal strains going against human natural defense system with the aim of contributing to upcoming biochemical discoveries of new medicines and treatments. Vy Khanh Cat Nguyen is an undergraduate pharmacy student at the University of Medicine and Pharmacy at Ho Chi Minh City, focusing on microbiology and forensic pharmacy. Her interests include antibiotic resistance, beneficial bacteria in organic cosmetics, and the application of microbiology in pharmaceutical forensics. She aims to pursue advanced studies to contribute to research and innovation in this combined field.

Mr. Bui Quoc Huy is a researcher specializing in microbiology and biotechnology, with a strong focus on the application of microbial systems for environmental and industrial solutions. In the field of environmental biotechnology, Mr. Huy has worked on expressing and optimizing PET-degrading enzymes in E. coli BL21, aiming to provide sustainable solutions for plastic waste management. In parallel, Mr. Huy has contributed to probiotic research, focusing on the isolation, production, and functional evaluation of beneficial microorganisms intended for health applications. Additionally, Mr. Huy has utilized the wax moth larva (Galleria mellonella) as an in vivo infection model to study microbial pathogenicity and host–microbe interactions, offering valuable insights into the safety and efficacy of probiotic strains and antimicrobial. Looking forward, Mr. Huy aspires to expand interdisciplinary collaborations, aiming to translate laboratory findings into real-world biotechnological innovations.

Mr. Huy Nguyen-Thanh is a dedicated researcher specializing in biotechnology and microbiology. As the presenting author of the current project on phage display of nanobodies, Mr. Huy has contributed significantly to the development of innovative strategies for the selection of high-affinity nanobodies against multidrug-resistant bacteria. With a strong academic background and hands-on experience in phage display techniques, Mr. Huy has led the project through key stages of phage library construction. Mr Huy’s work is driven by a great passion for recombinant technology, aiming to bridge the gap between laboratory discoveries and clinical solutions. Known for a collaborative spirit, Mr. Huy is eager to engage with fellow scientists and professionals at the conference to exchange ideas, foster partnerships, and explore emerging trends in pharmaceutical research and development.

She is a first-year master's course student at the Graduate School of Pharmaceutical Sciences, Keio University and graduated from the Faculty of Pharmacy at Keio University in 2025. She is conducting research on the placenta under the supervision of Professor Masatoshi Tomi. She has been awarded the Nagai Foundation Tokyo Scholarship for Graduate Students by the Academy of Pharmaceutical Science and Technology, Japan in 2025.

2018–2024: B.S in Pharmacy, Tokyo University of Pharmacy and Life Sciences 2024–present: Doctoral course student, Graduate School of Pharmacy, Tokyo University of Pharmacy and Life Sciences 2025–present: JSPS Research Fellowship for Young Scientists (DC1)

Mr. Kanazawa is a researcher engaged in the study of drug delivery systems and therapies for age-related diseases. His current research focuses on the development of human serum albumin (HSA)-based nanoparticles for targeted drug delivery to injured muscle tissues. In particular, he is exploring the therapeutic potential of low molecular weight compounds, such as edaravone, that exhibit high binding affinity to HSA for the treatment of muscular disorders. He also utilizes molecular docking simulations to evaluate drug–HSA interactions and assess potential competition or synergy among candidate compounds. Leveraging his background in pharmacology and molecular biology, he aims to establish innovative treatment strategies through nanotechnology-based delivery platforms. He is currently affiliated with Kumamoto University, where he is involved in interdisciplinary research projects that include in vivo evaluations. His research seeks to bridge fundamental science and clinical application, with the goal of improving therapeutic outcomes in degenerative muscle diseases and age-related conditions.

Dr. Kim Yun Na received her Ph.D. in Agriculture from Gyeongsang National University and is currently working as a postdoctoral researcher at Gyeongsang National University. Dr. Kim Yun Na’s research focuses on the development of bioactive compounds from medicinal plants and herbal medicines, and the development of natural products-based materials for the treatment of benign prostatic hyperplasia and hair loss, and anti-aging.

Young Jun Kim is a PhD student in the College of Pharmacy at Korea University, working under the supervision of Prof. Ki Yong Lee. He earned his M.S. degree in Pharmacy from the same university. His research integrates bioassay-guided fractionation with metabolomics to dereplicate known compounds and efficiently identify and isolate novel bioactive compounds, with a particular focus on anti-allergic activity. His PhD research focuses on incorporating in silico approaches, including molecular docking, molecular dynamics, and network pharmacology, to explore the mechanisms of bioactive compounds.

Dr. Suvarna G. Kini is a Professor in the Department of Pharmaceutical Chemistry at Manipal College of Pharmaceutical Sciences, MAHE, Manipal. A dedicated medicinal chemist, Dr. Kini has made significant contributions to the field of pharmaceutical research, particularly in the area of oncology and infectious diseases. Her research focuses on the development of novel therapeutic agents, and has published 75 scientific papers, primarily addressing cancers such as breast, ovarian, and cervical, as well as tuberculosis.In recognition of her impactful research, Dr. Kini was awarded the prestigious BIOCARE grant by the Department of Science and Technology (DST), Government of India, in 2017. Through her academic and scientific pursuits, she received Association of Pharmaceutical Teachers of India’s , Prof. LVG Nargund research excellence Award in 2023. She continues to inspire and mentor future generations of pharmaceutical scientists, while contributing meaningfully to the global scientific community

I am currently a master’s student in the Department of Pharmacy at Pusan National University, specializing in pharmacokinetics and biopharmaceutics. My research focuses on developing and applying physiologically based pharmacokinetic (PBPK) models to evaluate the ADME properties and oral bioavailability of natural compounds. I am particularly interested in using PBPK modeling as a non-animal alternative to predict systemic exposure and reduce reliance on animal testing. Recently, I constructed PBPK models for umbelliferone in rats and humans using in vitro and in silico data. This study has been submitted to a peer-reviewed journal and is currently under review. Through this work, I aim to contribute to the advancement of animal-free testing methods by providing mechanistic and quantitative insights. I am especially motivated to support the application of these models in regulatory science, safety evaluation, and the development of functional and therapeutic products derived from natural sources.

Mr. Kubohira is a researcher in the Department of Physical Pharmaceutics, Graduate School of Pharmaceutical Sciences, Kumamoto University, Japan. His research is the development of therapeutic agents for cholesterol-related neurological disorders, such as Alzheimer's disease and Niemann-Pick disease type C, which involve pathological cholesterol accumulation in the brain, using cyclodextrins. Cyclodextrins are cyclic oligosaccharides known for their ability to dissolve cholesterol and reduce intracellular cholesterol accumulation. In particular, he focuses soluble cyclodextrin polymer, in which β-cyclodextrin is cross-linked with epichlorohydrin, and evaluate its kinetics, safety, and therapeutic effects in mice or human neuroblastoma cells. His research seeks to contribute to the development of brain-targeted therapies by demonstrating the potential of cyclodextrin-based materials to regulate cholesterol homeostasis. The ultimate goal is to provide new treatment strategies using cyclodextrins for neurodegenerative diseases that are currently difficult to treat.

Arief Kurniawan is a Ph.D. student at the College of Pharmacy, Yeungnam University, South Korea, under the supervision of Prof. Jeonghwan Kim. He holds both a B.Pharm (2014) and an M.Pharm (2022) in Pharmaceutical Sciences from Universitas Indonesia. His research is dedicated to advancing drug delivery systems, with a current focus on exploring mRNA and other RNA-based platforms, as well as developing innovative non-viral delivery vectors for gene therapy.

Hieu Le (Harry) is a pharmacist and Master of Philosophy candidate at the School of Pharmacy, the University of Sydney. He completed his Bachelor of Pharmacy (Honours Class I) at Hanoi University of Pharmacy, Vietnam. His research interests include the quality use of medicines, pharmacoepidemiology, and the care of older adults, particularly those living with dementia. He has contributed to eight peer-reviewed journal publications and actively participates in multidisciplinary research teams. Hieu is passionate about bridging clinical practice and research to improve health outcomes, with a strong focus on promoting safe and effective psychotropic use in vulnerable populations. He is also committed to fostering research collaboration between Vietnam and Australia, aiming to strengthen academic exchange and healthcare development in both countries.

Jun Hak Lee holds a B.S. in Pharmaceutical Engineering (Inje University, February 2023) and an M.S. in Pharmacy (Inje University, February 2025), where he developed selumetinib sulfate–loaded solid dispersions. Currently pursuing a Ph.D. in Pharmacy at Inje University, his research focuses on enhancing the properties of poorly water-soluble drugs through formulation strategies. Lee utilizes techniques like DSC, PXRD, FTIR, and in vitro dissolution testing, combined with machine learning for excipient selection and process optimization for solid dispersions, self-nanoemulsifying preconcentrates, and nanoparticles. He has co-authored six SCIE publications and presented at major conferences, including KSPST and AFPS.

Jun Hak Lee holds a B.S. in Pharmaceutical Engineering (Inje University, February 2023) and an M.S. in Pharmacy (Inje University, February 2025), where he developed selumetinib sulfate–loaded solid dispersions. Currently pursuing a Ph.D. in Pharmacy at Inje University, his research focuses on enhancing the properties of poorly water-soluble drugs through formulation strategies. Lee utilizes techniques like DSC, PXRD, FTIR, and in vitro dissolution testing, combined with machine learning for excipient selection and process optimization for solid dispersions, self-nanoemulsifying preconcentrates, and nanoparticles. He has co-authored six SCIE publications and presented at major conferences, including KSPST and AFPS.

Chang Soo Lee is a pharmacy student at Inje University, focusing on physicochemical characterization, drug solubilization, and development of generic and repositioned drugs.

Chang Soo Lee is a pharmacy student at Inje University, focusing on physicochemical characterization, drug solubilization, and development of generic and repositioned drugs.

Ziyan Liao is a graduate student form the college of Pharmaceutical Sciences at Zhejiang University. She is a biomedical researcher specializing in drug delivery, biomaterials, and cancer immunotherapy. Her research focuses on engineered platforms for CAR-T cell therapy and tumor microenvironment modulation.

Hello, my name is Yipeng Lin. I am currently pursuing a PhD at the Sydney Pharmacy School, University of Sydney. I am conducting a research project titled *"Exploring Vision-Protecting Agents from Australian Propolis"* under the supervision of Dr. Fanfan Zhou. I have obtained some preliminary results, and I am delighted to have this opportunity to share my research findings with everyone interested！I hope to meet more interesting people through this event and exchange ideas with one another. I can’t wait to see you all!

Haiyang Yu received his Ph.D. from Dong-A University in South Korea and subsequently conducted postdoctoral research at the Cancer Institute of New Jersey in the United States. In 2015, he joined the Institute of Traditional Chinese Medicine at Tianjin University of Traditional Chinese Medicine as a professor, where he primarily focuses on researching the mechanisms of Traditional Chinese Medicine and natural products in the prevention and treatment of cancer.

Xinyang Liu is a Ph.D. candidate at the Institute of Chinese Medical Sciences (ICMS), University of Macau, Macau, China. Her research focuses on physiologically based pharmacokinetic (PBPK) modeling, pharmacokinetics/pharmacodynamics (PK/PD), and individualized drug therapy, particularly in the context of pregnancy-induced hypertension. With a background as a clinical pharmacist, she brings valuable real-world clinical insight into her research, bridging the gap between computational pharmacology and patient care. Her current work integrates modeling approaches with clinical parameters to support precision dosing strategies in vulnerable populations such as pregnant women. She is actively engaged in interdisciplinary collaboration, combining pharmacology, bioinformatics, and maternal-fetal medicine. Xinyang Liu is dedicated to improving the safety and efficacy of pharmacotherapy during pregnancy, and her work contributes to the development of more personalized and evidence-based treatment protocols. She continues to explore the translational potential of model-informed drug development in clinical settings.

Xinyang Liu, born in 1994, is a pharmacist at the Hospital of Zhengzhou University and currently a Ph.D. candidate at the Institute of Chinese Medical Sciences, University of Macau. She obtained her M.Sc. in Pharmaceutical Analysis from Zhengzhou University in July 2019, focusing on the design of targeted anti-tumor formulations. From August 2018 to December 2019, she worked as a research assistant in Prof. De-Fang Ouyang’s lab, specializing in AI-assisted drug formulation design. Since 2022, her Ph.D. research has focused on developing AI-integrated PBPK/PD models for precision medicine. She has published 14 SCI papers (4 as first author) and holds one patent.

Dr. Lu is a Professor in University of Macau. He received his Ph.D. degree in Shanghai Institute of Meteria Medica, Chinese Academy of Sciences in 2009. Currently, Prof. Lu is mainly engaged in the discovery and mechanism study of anti-cancer compounds based on tumor microenvironment. He is also interested in studying the new targets and strategies for cancer therapy. Prof. Lu has published more than 200 scientific papers in the SCI journals (Total citations 12000+, H-index 56, Scopus). He was awarded as the 2nd Prize of Natural Science: Macao Science and Technology Awards (twice) and CNPHARS Annual Young Pharmacologists.

Ayako Maeda-Minami is an assistant professor at Tokyo University of Sciences, where she has been engaged in education and research in pharmaceutical science. A licensed pharmacist in Japan, she holds a Doctor of Pharmaceutical Sciences from Keio University and a Master of Agriculture from Kyoto University. Her research specializes in Kampo medicine and the large-scale data analysis of drug repositioning. Dr. Maeda has made contributions to the field, including the development of a machine learning model for predicting Japanese Kampo diagnostic patterns and advancing disease prevention strategies through the analysis of large-scale medical data. She has also developed a novel drug information provision system for Kampo medicine using natural language processing technology for pharmacists.

Payel Mal is a research scholar at the Department of Pharmaceutical Chemistry, Manipal College of Pharmaceutical Sciences, Manipal, Karnataka, India, currently engaged in an industry-funded project. She holds a master’s degree in pharmacology and possesses expertise in natural product chemistry, cellular dynamics, metabolic disorders, pharmacology, and analytical techniques. Payel has contributed significantly to scientific literature, having published five review articles, one research article, and one book chapter so far. She is committed to continuous professional and personal development, actively seeking opportunities to expand her skills. Payel emphasizes the importance of reproducibility in research, believing that scientific findings should translate into tangible healthcare benefits rather than remaining confined to academic pursuits. Her approach combines rigorous research with a practical focus on real-world applications, reflecting her dedication to advancing healthcare wellness through reliable and impactful scientific work. Google scholar ID: https://scholar.google.com/citations?user=mZlqdg8AAAAJ&hl=en

Education Sep. 2023~ Korea National University of Science and Technology (UST) Present School of Korea Institute of Toxicology Advisor: Prof. Kang-Hyun Han Jan. 2016~ Alteogen Inc. Researcher Jun. 2023 Mar. 2014~ CNU Feb. 2016 Department of Chemical Engineering and Applied Chemistry, Master degree Advisor: Dong-Myung Kim Mar. 2008~ Chungnam National University (CNU) Feb. 2014 Department of Chemical Engineering and Applied Chemistry, Bachelor degree International Journal 1. Min et al., 2025. “Comparative study on the toxicity of Polygonum Multiflorum Radix: Assessment of decoction extract and powder in single-dose and 13-week repeated-dose toxicity studies in Sprague-Dawley rats”, J. Ethnopharmacol. Available online May, 120064 2. Min et al., 2024. “Evaluating the toxicity of the roots of Asarum heterotropoides var. mandshuricum extracted using the decoction method: Genotoxicity, single-dose toxicity, and 13-week repeated-dose toxicity studies”, J. Ethnopharmacol. May 10;325:117783. 3. Min et al., 2016. “Cell-free production and streamlined assay of cytosol-penetrating antibodies”, Biotechnol. Bioeng. Oct;113(10):2107-12.

Prof. Min is a natural product chemistry. He is studying the bioactive compounds of natural products.

Chunna Yadav has a Masters degree in Pharmaceutics and three published research articles. In addition to his work on formulation, HPLC and LC-MS/MS and microbial culture, he has built a Jeep around the engine of a 3-ton lorry, with which he horrifies his research institute's campus.

Dr. Tokio Morita is a researcher at the Division of Drugs, National Institute of Health Sciences (NIHS), Japan. He obtained his Ph.D. in Pharmacy from Keio University in 2021, where he studied food–drug interactions involving intestinal transporters. After working at Taiho Pharmaceutical in a pharmacokinetics laboratory, he joined NIHS in 2022. His current work focuses on regulatory science, particularly the development of in vitro methods for evaluating the bioequivalence of generic drugs. His recent studies include the impact of pharmaceutical excipients on drug permeability, the use of organoids for predicting intestinal absorption, and the in vitro assessment of nasal spray bioequivalence.

The importance of formulation design, which is the key technology of enhancing drug efficacy and reduction of side effects, is increasing in the advance of the drugs from low-molecular compounds to peptide/protein, DNA/functional nucleic acid and cytomedicine. On the other hand, in the development of a novel dosage form, which is a basis of product lifecycle management, including generic medicines, pharmaceutical design is the most important factor to determine the worth of the products, because the drug itself in the newly developed products is the same as that in the previous or conventional products. Therefore, to contribute to the development of future medicines such as DNA, functional nucleic acid and cytomedicine, we are trying design and evaluation of integrated DDS (iDDS), which combine existing drug carriers of dendrimer, liposomes, and polyethylene glycol with cyclodextrins according to the drug properties.

Taiki Nagatomo is an Assistant Professor at the School of Pharmacy, Nihon University, working on the development of intranasal formulations to improved the physicochemical properties of drugs. He earned his Bachelor’s degree in Pharmacy and obtained his pharmacist license in 2020. He has served as an Assistant Professor since 2022.

I'm B3 student in Department of clinical pharmacology of Tokushima University in Japan. I research about the development of novel microglia-targeted therapies using EVs.

Dr. Mohammad Nasri is a multi-disciplinary researcher in the Sydney School of Pharmacy. After receiving a Doctorate in Medicine, he continued his academic education in Medical Genetics, and then in Biomedical Engineering, Chemical Engineering (theme: nanotechnology, drug delivery to the CNS and bypassing the BBB), Biomaterials & 3D printing, and Pharmaceutical Sciences (theme: nanomedicine & targeted therapy for MDR cancers). In more than 2 decades of academic experience and 15 years of inter-disciplinary research, alongside his clinical profession, he’s been dedicated to high-qualified work, and precision in laboratory procedures. As a hard-working and dedicated researcher, Mohammad devotes his orientation to creativity, innovation, analytical reasoning, and critical thinking to steadily gain ground in his objectives in biomedical & life sciences. His research focuses on further advances in pharmaceutics, controlled & targeted therapy, nanomedicines, biomaterials & tissue engineering, 2D & 3D cell culture, regenerative medicine, and genome editing tools

Dr.Thuy Nguyen is a lecturer at Facuty of pharmaceutical administration and pharmacoeconomic in Hanoi University of Pharmacy. Her areas of interest and research include pharmaceutical service at hospital, community pharmacy, management of antimicrobial use at community, policy in pharmaceutical, drug supply management and the application of artificail intelligence in health care.

Thi Tuyet Nhung Nguyen is a lecturer at the Faculty of Pharmacy, Lac Hong University, Vietnam, and currently a PhD candidate in Clinical Drug Development of Herbal Medicine at Taipei Medical University, Taiwan. Her research focuses on the isolation, characterization, and biological evaluation of Vietnamese medicinal plants, utilizing advanced analytical chemistry systems including HPLC and UPLC-MS/MS-QTOF combined with chemoinformatic and bioinformatic tools. She specializes in investigating the pharmaceutical effects and identifying bioactive components from natural products. She also holds a Master’s degree in Drug Quality Control and Toxicology. Her current work emphasizes integrative strategies to enhance herbal drug discovery and quality control.

Dedicated and self-motivated researcher with 10+years experience of optimizing bioprocess and resolving issues in bioproduct formulation. Eager to leverage experiment conducting and data interpreting skills. Developed a total of 5 bioproduct formulations and bioprocess protocols. Collaborated on 3+ projects of probiotic development. Contributed to developing the cell machine interface to control bioprocessing and published 7+ article in bioengineering and biopharmaceutical topic.

Within three years of returning to Vietnam and setting up the laboratory of molecular microbiology and pathogenesis, Faculty of Pharmacy, her research interests include molecular diagnostics of microbial pathogens in animals and humans. Her team has already developed PCR, real-time PCR, and loop-mediated isothermal amplification (LAMP) based diagnostics of nosocomial infections by fungi, bacteria, and viruses. Her team has successfully developed multiplex PCR-based detection of Acinetobacter spp. and Candida spp. So, they believe that they have the ability and experience to be involved in producing this innovative, practical platform for high-throughput screening of novel synthetic substances and natural compounds to overcome antibiotic resistance.

Miss Nishinoiri is a researcher at Kumamoto University specializing in the field of metabolic dysfunction-associated steatotic liver disease (MASLD). Her research focuses on elucidating the regulatory mechanisms of glucose and lipid metabolism, with a particular interest in the role of alpha-1-acid glycoprotein (AGP), an acute-phase protein known to be involved in inflammatory and metabolic processes. Using AGP-knockout (AGP-KO) mice, she investigates how the absence of AGP affects metabolic homeostasis and contributes to the progression of liver disease. Her work integrates molecular biology techniques and animal models to explore potential therapeutic targets for MASLD and related metabolic disorders. Through her research, she aims to contribute to a better understanding of the pathophysiological links between inflammation, metabolic imbalance, and liver disease, ultimately advancing strategies for early intervention and treatment.　

Ms Yihe Niu is a PhD student in the Molecular Drug Development Group at Sydney Pharmacy School, University of Sydney. Her research investigates the role of glutamine metabolism in uveal melanoma, aiming to uncover metabolic vulnerabilities in this aggressive cancer. She has a strong academic interest in cancer biology and metabolic regulation, with a particular focus on how metabolic dependencies influence tumour growth and therapeutic sensitivity. Her work contributes to ongoing efforts to characterise the metabolic complexity of uveal melanoma.

Miss Alvena Noor is a dedicated Pharm.D. candidate at Ziauddin University with a strong academic background and a passion for pharmaceutical sciences. Throughout her studies, she has demonstrated a keen interest in clinical research, drug development, and public health, focusing on antimicrobial resistance and stewardship in low-resource settings. Alvena actively engages in interdisciplinary projects that bridge academic knowledge with practical healthcare solutions. She has contributed to research initiatives aimed at improving community health outcomes and is committed to advancing evidence-based practices in pharmacy.

Miss Alvena Noor is a dedicated Pharm.D. student at Ziauddin University with a strong academic interest in the intersection of traditional medicine, neuroscience, and pharmaceutical innovation. She is actively engaged in multiple international certification programs, including digital marketing, health emergency operations, neurology, and drug development from institutions such as WHO, Google, Yale, and the University of California. Alvena is currently working on a Review based manuscript focusing on antimicrobial resistance and community-level stewardship for submission to the Bulletin of the World Health Organization. She is particularly passionate about exploring integrative approaches in healthcare, combining modern pharmaceutical practices with traditional and indigenous systems. Her ongoing Literature work includes the role of cannabis-based medicines and psychedelics in neurological and psychiatric disorders. Known for her academic rigor, curiosity, and cross-disciplinary approach, she aims to contribute meaningfully to the evolving landscape of global health and therapeutics. This is her first time presenting at AFPS.

Mr. Christopher Busayo Olowosoke is a distinguished scholar, entrepreneur, and researcher. He is the founder and CEO of B.Khrease Academic Consult, research fellow at the Institute of Bioinformatics and Molecular Therapeutics (IBMT) and the Computer-aided Therapeutic Discovery and Design Platform (CATDD), where he actively contributes to advancements in biotechnology and drug discovery research. Christopher is affiliated with other professional organizations and his work have earned him multiple prestigious awards and grants, including recognition from the UNESCO-International Centre for Biotechnology under the Food and Health Security thematic area in 2021, the American Society for Nutrition Early Career Scientists (ASN-ECS) on Professional Development in 2022, and the New Frontiers in Research Fund on International Joint Initiative for Research in Climate Change Adaptation and Mitigation in 2023. His scholarly achievements extend to authoring and co-authoring numerous publications related to drug discovery for human disease and initiatives aimed at enhancing student writing skills.

Mr. Christopher Busayo Olowosoke is a distinguished scholar, entrepreneur, and researcher. He is the founder and CEO of B.Khrease Academic Consult, research fellow at the Institute of Bioinformatics and Molecular Therapeutics (IBMT) and the Computer-aided Therapeutic Discovery and Design Platform (CATDD), where he actively contributes to advancements in biotechnology and drug discovery research. Christopher is affiliated with other professional organizations and his work have earned him multiple prestigious awards and grants, including recognition from the UNESCO-International Centre for Biotechnology under the Food and Health Security thematic area in 2021, the American Society for Nutrition Early Career Scientists (ASN-ECS) on Professional Development in 2022, and the New Frontiers in Research Fund on International Joint Initiative for Research in Climate Change Adaptation and Mitigation in 2023. His scholarly achievements extend to authoring and co-authoring numerous publications related to drug discovery for human disease and initiatives aimed at enhancing student writing skills.

Rin Onaga is currently a student at the Graduate School of Pharmaceutical Sciences, Kumamoto University, and belongs to the department of physical pharmaceutics. His research focuses on developing drugs to improve cholesterol accumulation in the liver, a key factor in the pathogenesis of metabolic dysfunction-related steatohepatitis (MASH) by cyclodextrin derivatives. He is particularly fascinated by the multiple potential of cyclodextrins to serve as drug delivery carriers and active pharmaceutical ingredients. He also hopes to utilize their unique properties to design novel therapeutic strategies that can be applied in clinical practice.

Riuna is undertaking a Masters by research at The University of Western Australia. She has previously completed her Bachelor of Biomedical Science, with majors in Pathology and Pharmacology at UWA in 2021, and received First-Class Honours in Medical Research the following year. Her Honours year thesis, titled "Formulating a sublingual tablet for edaravone" revealed promising results for a novel sublingual edaravone formulation, and thus she was able to apply for and successfully receive an Australian Research Training Program scholarship to continue this research as her postgraduate project. In her time as a student thus far, she has successfully published an extensive literature review which outlined the lack of an oral edaravone formulation designed with input from the MND community in the current research space. She has also developed and validated a novel stability-indicating drug assay for edaravone quantification using HPLC.

Onigahara is an undergraduate student at Kumamoto University, majoring in Pharmaceutical Sciences. She is currently conducting research on novel drug delivery devices, with a particular focus on designing and evaluating vaccine formulations using needle-free intra-epidermal administration systems. Conventional injections can cause pain, fear, and even infection at the puncture site. Through this research, she is gaining insight into antigen delivery mechanisms and exploring how they can be leveraged to improve the efficacy and convenience of vaccines. She hopes this work will contribute to increasing global vaccine uptake. Onigahara also aims to apply the knowledge and experience gained from her research to support patients and promote the safe and effective use of medications. Although she is still exploring her specific interests, she values hands-on training and research as essential components of her learning. She looks forward to utilizing these experiences in her future career.

Ashutosh Kumar Pandey is currently pursuing his PhD in the Department of Pharmaceutical Chemistry at Manipal, where he has developed a robust expertise in drug development and animal models, with a particular focus on the 3Rs (Replacement, Reduction, and Refinement). He holds two patents—one Indian and one German—and has published three research articles. Throughout his research journey, Ashutosh has been selected for various government-funded workshops, reflecting his commitment to advancing scientific knowledge. During his PhD, he has received two travel grants to present his research at national and international conferences. Presently, he is engaged in an industry-funded project, further broadening his research experience. Additionally, Ashutosh has worked at the Council of Scientific & Industrial Research (CSIR), where he contributed to herbal drug discovery. His diverse achievements highlight his dedication to pharmaceutical innovation and his growing reputation in the field of drug research and development.

Mr. Dilip Panwar is an senior research fellow in the Division of Pharmaceutics and Pharmacokinetics at Council of Scientific and Industrial Research - Central Drug Research Institute, Lucknow, India. He holds a M.S (Pharm) in Pharmaceutics from National Institute of Pharmaceutical Education and Research, Hyderabad and has a experience in drug delivery systems. His research focuses on the development of targeted nanoformulations and Microneedles for transdermal drug delivery. His recent work integrates nano-pharmaceutics into advanced therapeutic strategies, aligning with the theme of this conference.

Sung Mo Park is a master’s student at the College of Pharmacy, Inje University, under the supervision of Professor Kwan Hyung Cho. He earned his B.S. in Pharmaceutical Engineering from Inje University and has research interests in drug solubilization, stabilization, and physicochemical characterization of pharmaceutical compounds. He has co-authored SCIE-indexed publications, including studies on gastroretentive combination tablets for Helicobacter pylori eradication and supersaturated gel formulations to improve drug solubility and stability.

Jin Woo Park is a master's student in the College of Pharmacy at Inje University, Republic of Korea, under the supervision of Professor Kwan Hyung Cho. He earned his bachelor's degree in pharmaceutical engineering from the same university, graduating with distinction. His research focuses on drug solubilization, stabilization, and formulation development, particularly for poorly soluble compounds. He has authored publications in leading journals such as Molecules, Pharmaceutics, and Gels, highlighting innovative work on supersaturated formulations and gastroretentive drug delivery systems. His current interests include the design of incrementally modified drugs, the application of physicochemical principles in drug repositioning, and advanced formulation strategies such as SNEDDS and sustained-release systems.

Jin Woo Park is a master's student in the College of Pharmacy at Inje University, Republic of Korea, under the supervision of Professor Kwan Hyung Cho. He earned his bachelor's degree in pharmaceutical engineering from the same university, graduating with distinction. His research focuses on drug solubilization, stabilization, and formulation development, particularly for poorly soluble compounds. He has authored publications in leading journals such as Molecules, Pharmaceutics, and Gels, highlighting innovative work on supersaturated formulations and gastroretentive drug delivery systems. His current interests include the design of incrementally modified drugs, the application of physicochemical principles in drug repositioning, and advanced formulation strategies such as SNEDDS and sustained-release systems.

Professor at College of Pharmacy, Dankook University, South Korea. Major reserach fields are natural products which are beneficial for presenting Alzheimer's disease

Jin Woo Park is a master's student in the College of Pharmacy at Inje University, Republic of Korea, under the supervision of Professor Kwan Hyung Cho. He earned his bachelor's degree in pharmaceutical engineering from the same university, graduating with distinction. His research focuses on drug solubilization, stabilization, and formulation development, particularly for poorly soluble compounds. He has authored publications in leading journals such as Molecules, Pharmaceutics, and Gels, highlighting innovative work on supersaturated formulations and gastroretentive drug delivery systems. His current interests include the design of incrementally modified drugs, the application of physicochemical principles in drug repositioning, and advanced formulation strategies such as SNEDDS and sustained-release systems.

Jin Woo Park is a master's student in the College of Pharmacy at Inje University, Republic of Korea, under the supervision of Professor Kwan Hyung Cho. He earned his bachelor's degree in pharmaceutical engineering from the same university, graduating with distinction. His research focuses on drug solubilization, stabilization, and formulation development, particularly for poorly soluble compounds. He has authored publications in leading journals such as Molecules, Pharmaceutics, and Gels, highlighting innovative work on supersaturated formulations and gastroretentive drug delivery systems. His current interests include the design of incrementally modified drugs, the application of physicochemical principles in drug repositioning, and advanced formulation strategies such as SNEDDS and sustained-release systems.

Sung Mo Park is a master’s student at the College of Pharmacy, Inje University, under the supervision of Professor Kwan Hyung Cho. He earned his B.S. in Pharmaceutical Engineering from Inje University and has research interests in drug solubilization, stabilization, and physicochemical characterization of pharmaceutical compounds. He has co-authored SCIE-indexed publications, including studies on gastroretentive combination tablets for Helicobacter pylori eradication and supersaturated gel formulations to improve drug solubility and stability.

Thi-Phuong-Thao Pham is a young master’s student at the Graduate Institute of Pharmacy, China Medical University (Taiwan), with a growing research portfolio in evidence-based pharmacology in the dry lab. Since beginning her research in 2023, she has authored 14 publications, earned 14 citations, and holds an H-index of 3. Her work spans topics such as herbal interventions for pediatric infections, adjunctive treatments in critical care, and the comparative bioavailability of omega-3 fatty acids, with publications in journals including Food Chemistry X and Journal of Functional Foods. Pham is particularly skilled in literature synthesis, R-based statistical modeling, and scientific visualization. Looking ahead, she is shifting her focus toward drug resistance and pharmacogenomics—exploring how genetic polymorphisms influence variability in drug response—by integrating both experimental and clinical data. She plans to deepen this direction throughout her master’s and PhD training, to identify predictive biomarkers and optimize personalized therapies in oncology and infectious diseases.

apt. Yennie Agnes Pranata, M.S.Farm is a pharmacist and postgraduate researcher in the Master’s Program in Pharmacy with a strong focus on natural product pharmacology and inflammation-related pathologies. She holds a Bachelor's degree in Pharmacy and has earned her professional pharmacist license (Apt) in Indonesia. Her research interests include the pharmacological effects of medicinal plants, especially the modulation of inflammatory mediators using herbal combinations. Her most recent work investigates the synergistic anti-inflammatory potential of turmeric (Curcuma longa) and black pepper (Piper nigrum), aiming to overcome the bioavailability challenges of curcumin. She is passionate about bridging traditional herbal medicine with modern pharmaceutical science, promoting evidence-based use of natural compounds. She is committed to contributing to the advancement of phytopharmacology research, particularly in the development of safe and effective plant-based therapeutics for chronic inflammatory conditions.

Dr. Aditya Dev Rajora is currently working as an Assistant Professor in the Department of Pharmaceutical Quality Assurance at Manipal College of Pharmaceutical Sciences (MCOPS), Manipal Academy of Higher Education (MAHE), Manipal, Karnataka, India. He earned his Ph.D. in Pharmaceutical Sciences from Birla Institute of Technology, Mesra, during which he was awarded the Prestigious National Doctoral Fellowship (NDF) by the All India Council for Technical Education (AICTE), Government of India. He has also worked as a Postdoctoral Research Associate in the Department of Biomedical Engineering at the Indian Institute of Technology, Hyderabad. Dr. Rajora has published eight research papers, including five in Q1-ranked journals, and has contributed to twelve book chapters. He has participated in four national and international conferences. His primary research focuses on the development of biomaterials for tissue regeneration.

L Sasongko is A/Prof at Dept of Pharmaceutics, School of Pharmacy, Institut Teknologi Bandung. I did PhD at School of Pharmacy, the University of Sydney. While my main teaching and research are in the area of pharmaceutic, I am also teaching in Master of Pharmaceutical Industry, which one of the research I will be presenting in this conference. I am also doing consultation for pharmaceutical industry and bioequivalence lab. Besides teaching, I involve in curriculum development, education commission, human ethics committee, academic misconduct commission, auditor for university internal quality audit, assessor of independent accreditation institution for health colleges, and committee of Indonesian Pharmacists Association.

L Sasongko is A/Prof at Dept of Pharmaceutics, School of Pharmacy, Institut Teknologi Bandung. I did PhD at School of Pharmacy, the University of Sydney. While my main teaching and research are in the area of pharmaceutic, I am also teaching in Master of Pharmaceutical Industry, which one of the research I will be presenting in this conference. I am also doing consultation for pharmaceutical industry and bioequivalence lab. Besides teaching, I involve in curriculum development, education commission, human ethics committee, academic misconduct commission, auditor for university internal quality audit, assessor of independent accreditation institution for health colleges, and committee of Indonesian Pharmacists Association.

Yuhi Shintani is a PhD student at Kumamoto University, specializing in the development of protein-based therapeutics for metabolic liver diseases. Their research focuses on the pharmacological evaluation of HSA-mFGF21, a recombinant fusion protein designed to enhance the half-life and efficacy of native FGF21, in the treatment of MASLD. They integrate in vivo disease models, transcriptomic analysis, and structural modeling to elucidate its mechanism of action. Yuhi Shintani has presented their work at national and international conferences and aims to bridge basic science and clinical application. Their long-term goal is to develop innovative therapies that target multiple pathways involved in chronic liver disease progression.

Mr. K M Yasif is a PhD student in the Division of Pharmacy, School of Allied Health, University of Western Australia. His research project is focused on developing a validated High-Performance Thin-Layer Chromatography (HPTLC) tool for evaluating targeted molecules in complex matrices. He has been awarded the UWA International Fee Scholarship and the University Postgraduate Award for pursuing a PhD. He completed his Bachelor of Pharmacy (B. Pharm.) and Master of Pharmacy (M. Pharm.) in Pharmaceutical Technology from the University of Dhaka, Bangladesh. After completing postgraduation, he joined a reputed pharmaceutical company and later joined the Department of Pharmaceutical Technology, University of Dhaka, Bangladesh, as a lecturer. He's currently holding the position of Assistant Professor in the same department with a study leave for pursuing his higher degree by research at the University of Western Australia. His research interests cover pharmaceutical analytical chemistry, pharmaceutics and pharmacy practice.

Mr. K M Yasif is a PhD student in the Division of Pharmacy, School of Allied Health, University of Western Australia. His research project is focused on developing a validated High-Performance Thin-Layer Chromatography (HPTLC) tool for evaluating targeted molecules in complex matrices. He has been awarded the UWA International Fee Scholarship and the University Postgraduate Award for pursuing a PhD. He completed his Bachelor of Pharmacy (B. Pharm.) and Master of Pharmacy (M. Pharm.) in Pharmaceutical Technology from the University of Dhaka, Bangladesh. After completing postgraduation studies, he joined a reputed pharmaceutical company and later joined the Department of Pharmaceutical Technology, University of Dhaka, Bangladesh, as a lecturer. He's currently holding the position of Assistant Professor in the same department with a study leave for pursuing his higher degree by research at the University of Western Australia. His research interests cover pharmaceutical analytical chemistry, pharmaceutics and pharmacy practice.

Kazuaki Taguchi, Ph.D., is a Professor at the Graduate School of Biomedical and Health Sciences, Hiroshima University, Japan. He received his B.Sc., M.Sc., and Ph.D. in Pharmaceutical Science from Kumamoto University, specializing in Biopharmaceutics. Dr. Taguchi is a licensed pharmacist and has held academic positions at Sojo University (Kumamoto, Japan) and Keio University (Tokyo, Japan). From 2015 to 2016, he was a visiting fellow at the University of New South Wales in Sydney, Australia. His research focuses on drug delivery systems, protein engineering, and pharmacokinetics, with the aim of improving therapeutic efficacy and safety.

Dr. Toru Taharabaru is an Assistant Professor at the Graduate School of Pharmaceutical Sciences, Kumamoto University. He received his Ph.D. in Pharmaceutical Sciences from Kumamoto University in 2023, during which he was also a Research Fellow of the Japan Society for the Promotion of Science (JSPS). Following the completion of his doctoral studies, he continued his research as a JSPS Postdoctoral Fellow at Kumamoto University. He subsequently worked as a researcher at Otsuka Pharmaceutical Co., Ltd. Since 2025, Since 2025, he has worked as an assistant professor at the Graduate School of Pharmaceutical Sciences. His research focuses on drug delivery systems and biomedical engineering.

Catherine TULEU, Docteur en Pharmacie, PhD, is Professor in Paediatric Pharmaceutics at UCL School of Pharmacy, UK. (https://orcid.org/0000-0001-8384-357X ; H-index 40) Her research, inherently translational, ranges from formulation, methodology development to clinical implementation, integrating the following themes: children centric excipient research; repurposing by reformulating for better medicines for children; development of innovative age appropriate dosage forms (especially for under 5s); administration issues and devices and sensory pharmaceutics (dosage form acceptability and in vitro/in vivo taste assessment). https://www.ucl.ac.uk/pharmacy/people/professor-catherine-tuleu Her spin out company senCeuTics Ltd. specializes in pharmaceutical sensory evaluation and offers a full spectrum of preclinical, clinical and paediatric formulation services under one roof. https://senceutics.com/ She is the founder and chairperson of the European Paediatric Formulation Initiative (EuPFI), a consortium working in a pre-competitive way on paediatric drug formulations. http://www.eupfi.org/ https://www.linkedin.com/in/catherine-tuleu-9b842214/

Catherine TULEU, Docteur en Pharmacie, PhD, is Professor in Paediatric Pharmaceutics at UCL School of Pharmacy, UK. (https://orcid.org/0000-0001-8384-357X ; H-index 40) Her research, inherently translational, ranges from formulation, methodology development to clinical implementation, integrating the following themes: children centric excipient research; repurposing by reformulating for better medicines for children; development of innovative age appropriate dosage forms (especially for under 5s); administration issues and devices and sensory pharmaceutics (dosage form acceptability and in vitro/in vivo taste assessment). https://www.ucl.ac.uk/pharmacy/people/professor-catherine-tuleu Her spin out company senCeuTics Ltd. specializes in pharmaceutical sensory evaluation and offers a full spectrum of preclinical, clinical and paediatric formulation services under one roof. https://senceutics.com/ She is the founder and chairperson of the European Paediatric Formulation Initiative (EuPFI), a consortium working in a pre-competitive way on paediatric drug formulations. http://www.eupfi.org/ https://www.linkedin.com/in/catherine-tuleu-9b842214/

Catherine TULEU, Docteur en Pharmacie, PhD, is Professor in Paediatric Pharmaceutics at UCL School of Pharmacy, UK. (https://orcid.org/0000-0001-8384-357X ; H-index 40) Her research, inherently translational, ranges from formulation, methodology development to clinical implementation, integrating the following themes: children centric excipient research; repurposing by reformulating for better medicines for children; development of innovative age appropriate dosage forms (especially for under 5s); administration issues and devices and sensory pharmaceutics (dosage form acceptability and in vitro/in vivo taste assessment). https://www.ucl.ac.uk/pharmacy/people/professor-catherine-tuleu Her spin out company senCeuTics Ltd. specializes in pharmaceutical sensory evaluation and offers a full spectrum of preclinical, clinical and paediatric formulation services under one roof. https://senceutics.com/ She is the founder and chairperson of the European Paediatric Formulation Initiative (EuPFI), a consortium working in a pre-competitive way on paediatric drug formulations. http://www.eupfi.org/ https://www.linkedin.com/in/catherine-tuleu-9b842214/

Catherine TULEU, Docteur en Pharmacie, PhD, is Professor in Paediatric Pharmaceutics at UCL School of Pharmacy, UK. (https://orcid.org/0000-0001-8384-357X ; H-index 40) Her research, inherently translational, ranges from formulation, methodology development to clinical implementation, integrating the following themes: children centric excipient research; repurposing by reformulating for better medicines for children; development of innovative age appropriate dosage forms (especially for under 5s); administration issues and devices and sensory pharmaceutics (dosage form acceptability and in vitro/in vivo taste assessment). https://www.ucl.ac.uk/pharmacy/people/professor-catherine-tuleu Her spin out company senCeuTics Ltd. specializes in pharmaceutical sensory evaluation and offers a full spectrum of preclinical, clinical and paediatric formulation services under one roof. https://senceutics.com/ She is the founder and chairperson of the European Paediatric Formulation Initiative (EuPFI), a consortium working in a pre-competitive way on paediatric drug formulations. http://www.eupfi.org/ https://www.linkedin.com/in/catherine-tuleu-9b842214/

Catherine TULEU, Docteur en Pharmacie, PhD, is Professor in Paediatric Pharmaceutics at UCL School of Pharmacy, UK. (https://orcid.org/0000-0001-8384-357X ; H-index 40) Her research, inherently translational, ranges from formulation, methodology development to clinical implementation, integrating the following themes: children centric excipient research; repurposing by reformulating for better medicines for children; development of innovative age appropriate dosage forms (especially for under 5s); administration issues and devices and sensory pharmaceutics (dosage form acceptability and in vitro/in vivo taste assessment). https://www.ucl.ac.uk/pharmacy/people/professor-catherine-tuleu Her spin out company senCeuTics Ltd. specializes in pharmaceutical sensory evaluation and offers a full spectrum of preclinical, clinical and paediatric formulation services under one roof. https://senceutics.com/ She is the founder and chairperson of the European Paediatric Formulation Initiative (EuPFI), a consortium working in a pre-competitive way on paediatric drug formulations. http://www.eupfi.org/ https://www.linkedin.com/in/catherine-tuleu-9b842214/

Catherine TULEU, Docteur en Pharmacie, PhD, is Professor in Paediatric Pharmaceutics at UCL School of Pharmacy, UK. (https://orcid.org/0000-0001-8384-357X ; H-index 40) Her research, inherently translational, ranges from formulation, methodology development to clinical implementation, integrating the following themes: children centric excipient research; repurposing by reformulating for better medicines for children; development of innovative age appropriate dosage forms (especially for under 5s); administration issues and devices and sensory pharmaceutics (dosage form acceptability and in vitro/in vivo taste assessment). https://www.ucl.ac.uk/pharmacy/people/professor-catherine-tuleu Her spin out company senCeuTics Ltd. specializes in pharmaceutical sensory evaluation and offers a full spectrum of preclinical, clinical and paediatric formulation services under one roof. https://senceutics.com/ She is the founder and chairperson of the European Paediatric Formulation Initiative (EuPFI), a consortium working in a pre-competitive way on paediatric drug formulations. http://www.eupfi.org/ https://www.linkedin.com/in/catherine-tuleu-9b842214/

Sanghyun Woo is a graduate student in the Lab of Physical & Industrial Pharmacy at Hanyang University, South Korea. Sung Giu Jin is a professor in the Department of Pharmaceutical Engineering at Dankook University, South Korea. Han-Gon Choi is a professor in the College of Pharmacy at Hanyang University, South Korea.

All authors are experts in the production and characterisation of nanoparticles for drug delivery system.

Shugo Yamashita is a assistant professor of Pharmacokinetics at Doshisha Women's College of Liberal Arts. His work focuses specifically on the material design using polypeptides and its application to drug delivery systems. Grinding coffee beans using manual grinder is his favourite time of the day.

Yi-Chun Ni is currently a graduate student at Taipei Medical University in Taiwan, with a strong academic background in life sciences. Her research focuses on cancer drug resistance and the application of AI-based molecular docking to predict drug structure modifications. She has hands-on experience in bioinformatics, which she integrates into her interdisciplinary approach to studying disease mechanisms and therapeutic strategies. Yi-Chun has also been involved in international research collaborations, which have enhanced her communication skills and ability to work effectively in diverse scientific environments. She is passionate about leveraging advanced computational and experimental tools to contribute to innovative cancer research and aims to further develop her career on a global scale.

Dr. Okhee Yoo, a Research Fellow in Pharmacy at The University of Western Australia, specialises in paediatric formulation and pharmacokinetic (PK) analysis. Her PhD at UWA focused on children's oral medications, involving population PK analysis and formulation. This experience led to her role as a Senior Research Officer, conducting pharmacometric analyses and dose optimisation for clinical trials. Dr. Yoo has since spearheaded innovative projects like preprocedural tablets and a high-dose anti-infective paediatric oral delivery platform. Her expertise in experimental design has also enhanced numerous collaborative projects. A dynamic and adaptable researcher, Dr. Yoo actively fosters interdisciplinary partnerships, significantly contributing to evidence-based, patient-centred therapeutics in WA through collaborations with leading researchers.

Dr. Okhee Yoo, a Research Fellow in Pharmacy at The University of Western Australia, specialises in paediatric formulation and pharmacokinetic (PK) analysis. Her PhD at UWA focused on children's oral medications, involving population PK analysis and formulation. This experience led to her role as a Senior Research Officer, conducting pharmacometric analyses and dose optimisation for clinical trials. Dr. Yoo has since spearheaded innovative projects like preprocedural tablets and a high-dose anti-infective paediatric oral delivery platform. Her expertise in experimental design has also enhanced numerous collaborative projects. A dynamic and adaptable researcher, Dr. Yoo actively fosters interdisciplinary partnerships, significantly contributing to evidence-based, patient-centred therapeutics in WA through collaborations with leading researchers.

formulation and pharmacokinetic (PK) analysis. Her PhD at UWA focused on children's oral medications, involving population PK analysis and formulation. This experience led to her role as a Senior Research Officer, conducting pharmacometric analyses and dose optimisation for clinical trials. Dr. Yoo has since spearheaded innovative projects like preprocedural tablets and a high-dose anti-infective paediatric oral delivery platform. Her expertise in experimental design has also enhanced numerous collaborative projects. A dynamic and adaptable researcher, Dr. Yoo actively fosters interdisciplinary partnerships, significantly contributing to evidence-based, patient-centred therapeutics in WA through collaborations with leading researchers.

Dr. Okhee Yoo, an Early- and Mid-Career Research Fellow in Pharmacy at The University of Western Australia, specialises in paediatric formulation and pharmacokinetic (PK) analysis. Her PhD at UWA focused on children's oral medications, involving population PK analysis and formulation. This experience led to her role as a Senior Research Officer, conducting pharmacometric analyses and dose optimisation for clinical trials. Dr. Yoo has since spearheaded innovative projects like preprocedural tablets and a high-dose anti-infective paediatric oral delivery platform. Her expertise in experimental design has also enhanced numerous collaborative projects. A dynamic and adaptable researcher, Dr. Yoo actively fosters interdisciplinary partnerships, significantly contributing to evidence-based, patient-centred therapeutics in WA through collaborations with leading researchers.

formulation and pharmacokinetic (PK) analysis. Her PhD at UWA focused on children's oral medications, involving population PK analysis and formulation. This experience led to her role as a Senior Research Officer, conducting pharmacometric analyses and dose optimisation for clinical trials. Dr. Yoo has since spearheaded innovative projects like preprocedural tablets and a high-dose anti-infective paediatric oral delivery platform. Her expertise in experimental design has also enhanced numerous collaborative projects. A dynamic and adaptable researcher, Dr. Yoo actively fosters interdisciplinary partnerships, significantly contributing to evidence-based, patient-centred therapeutics in WA through collaborations with leading researchers.

Haiyang Yu received his Ph.D. from Dong-A University in South Korea and subsequently conducted postdoctoral research at the Cancer Institute of New Jersey in the United States. In 2015, he joined the Institute of Traditional Chinese Medicine at Tianjin University of Traditional Chinese Medicine as a professor, where he primarily focuses on researching the mechanisms of traditional Chinese medicine and natural products in the prevention and treatment of cancer.

Dr. Zeb received Pharm-D and M.Phil. degrees from Gomal University (Pakistan), and earned his PhD from Hanyang University ERICA (South Korea) in 2017. Currently, he is working as a Research Associate Professor at PharmacoMicrobiomics Research Center in the College of Pharmacy, Hanyang University ERICA. Previously, he worked as a Post-doc fellow at the College of Pharmacy, Gachon University, South Korea (2021-2024). He also served Riphah International University, Pakistan as an Associate Professor (2017-2023). His research interests include the development of nano-formulations and drug delivery systems such as liposomes, lipid- and polymer-based nanoparticles, and hydrogels for improving therapeutic efficacy of drugs in cancer, inflammatory and neurological diseases. He holds two international patents in South Korea.

I am a third-year PhD student in the Department of Pharmacology and Pharmacy at the University of Hong Kong under the tutelage of Professor Aviva Chow. During my doctoral studies, I have developed extensive expertise in drug delivery research, with a particular focus on nanomedicine. My research centers on the development of nano-embedded microparticles for nose-to-brain drug delivery, a promising therapeutic strategy for brain-related diseases. Notably, my work has led to the successful fabrication of fingolimod nano-embedded microparticles as neuroprotective therapy for ischemic stroke, demonstrating significant neuroprotective effects in an animal model of ischemic stroke. This research has resulted in the publication of a first-author original research articles in the Drug Delivery and Translational Research. My research experience in the field has also helped me to contribute a first-author review article published in the International Journal of Pharmaceutics.

Jiaqi Zhao is a fourth-year Ph.D. candidate in the Laboratory of Precision Medicine and Biopharmaceuticals at Zhejiang University, supervised by Professor Liqiang Pan. The laboratory serves as a multidisciplinary platform integrating bioinformatics, biopharmaceutics, and immunology, dedicated to developing genomic medicine-driven personalized tumor immunotherapies and is a pioneer in China’s personalized cancer vaccines and novel antibody therapeutics. Her current research focuses on bispecific TCR-directed macrophage engagers (BiTME), an innovative immunotherapy that redirects macrophages to target neoantigen-expressing tumors through phagocytosis and tumor microenvironment remodeling. This approach aligns with next-generation personalized therapeutic strategies, aiming to translate genomic data into actionable immune interventions. Contact: 12419024@zju.edu.cn | (+86) 153-5504-0234.

Prof. Qi ZHAO obtained his PhD from the Department of Biochemistry at the Chinese University of Hong Kong. He conducted postdoctoral research at the National Cancer Institute (NCI) of the National Institutes of Health (NIH) in the United States and at the Memorial Sloan Kettering Cancer Center. He has served at the Faculty of Health Sciences, University of Macau since 2016. In recent years, he has published over 120 papers in journals such as Nature Communications, Leukemia, Journal of Hematology & Oncology, Cell Reports Medicine, Advanced Sciences, and Clinical Cancer Research. He has received the NIH Federal Technology Transfer Award and the Best Research Award of the university. He has led various research projects (total 17) and numerous industrial collaboration projects (Novo Nordisk, China Resources Pharm). He has filed 20 patents and completed the industrial translation of two antibody drugs. His research mainly focuses on antibody immunotherapy and drug delivery.

A/Prof. Fanfan Zhou is the Head of Pharmacology discipline at Sydney Pharmacy School, the University of Sydney. She received her PhD from Rutgers, the State University of New Jersey, USA and her bachelor's degree from China Pharmaceutical University. Her current research focuses on two main themes: drug discovery and development for cancers and retinal diseases as well as structure-function relationship and molecular regulation of human Solute Carrier Transporters. Her research also contributes to targeted drug design, pharmacogenomics of anti-cancer drugs and pharmacological research on natural compounds. To date, she has published >120 papers in the field of pharmaceutical science and pharmacology. She is currently the associate editor of 6 journals including Frontiers in Pharmacology, Frontiers in Oncology, Scientific Reports and Journal of Pharmacy and Pharmacology. She has been invited to review for a range of prestigious journals including Nature Communications and Advanced Sciences.

A/Prof. Fanfan Zhou is currently the Head of Pharmacology discipline and the Head of Molecular Drug Development Unit at the Sydney Pharmacy School, the University of Sydney. She received her PhD of Pharmaceutical Science from Rutgers, the State University of New Jersey, USA and her bachelor's degree from China Pharmaceutical University. Her laboratory research focuses on two main themes: drug discovery and development for cancers and retinal diseases as well as structure-function relationship and molecular regulation of human Solute Carrier Transporters. Her research also expands to targeted drug design, pharmacogenomics of drugs and pharmacological research on natural compounds.

A/Prof. Fanfan Zhou is the Head of Pharmacology discipline at Sydney Pharmacy School, the University of Sydney. She received her PhD from Rutgers, the State University of New Jersey, USA and her Bachelor’s degree from China Pharmaceutical University. Her current research focuses on two main themes: drug discovery and development for cancers and retinal diseases as well as structure-function relationship and molecular regulation of human Solute Carrier Transporters. Her research also contributes to targeted drug design, pharmacogenomics of anti-cancer drugs and pharmacological research on natural compounds. To date, she has published 124 SCI papers in the field of pharmaceutical science and pharmacology.